Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
Launched by UNIVERSITY OF SYDNEY · Dec 8, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain imaging techniques can help doctors track liver tumors during radiation therapy for liver cancer. Specifically, it focuses on patients who have received a special treatment called stereotactic ablative body radiation therapy (SABR) after a procedure known as trans-catheter arterial chemoembolization (TACE). The study will explore if the contrast agents used in imaging can be detected by a software called KIM, which helps in monitoring the tumors.
To participate in this trial, potential candidates should be between 18 and 74 years old, have received or will receive SABR treatment for liver cancer, and have been administered a specific type of contrast agent that shows up on imaging scans. Participants will not need to do anything extra apart from what is already part of their treatment, and they will need to provide consent to take part in the study. This research aims to improve how doctors can track tumors during treatment, which could lead to better care for patients with liver cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site.
- • Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan
- • The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking.
- • Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited)
- Exclusion Criteria:
- • Less than 18 years of age
- • Minimum image dataset is not available
- • Image dataset is not in a compatible format
About University Of Sydney
The University of Sydney is a leading research institution in Australia, renowned for its commitment to advancing medical science and improving healthcare outcomes through innovative clinical trials. With a robust infrastructure and a multidisciplinary team of experts, the university fosters a collaborative environment that integrates cutting-edge research with clinical practice. The institution emphasizes ethical standards, patient safety, and scientific rigor in its trials, aiming to translate findings into real-world applications that benefit diverse populations. Through its dedication to excellence and impact, the University of Sydney continues to contribute significantly to the fields of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Westmead, New South Wales, Australia
Woolloongabba, Queensland, Australia
Melbourne, Victoria, Australia
Waratah, New South Wales, Australia
Melbourne, Victoria, Australia
Patients applied
Trial Officials
Paul Keall, PhD
Study Chair
University of Sydney
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials